We are live on ! Find out more
CYTO

Altamira Therapeutics Ltd
CYTO

Delisted

CYTO was delisted on the 19th of December, 2024.

Back to rankings

7 hedge funds and large institutions have $9.5M invested in Altamira Therapeutics Ltd in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% more capital invested

Capital invested by funds: $9.03M → $9.5M (+$465K)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

22% less funds holding

Funds holding: 9 → 7 (-2)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
7
Holders Change
-2
Holders Change %
-22.22%
% of All Funds
0.17%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
1
Increased
1
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$122K
2
SPC
Sigma Planning Corp
Michigan
+$60.9K

Top Sellers

Rank Fund Capital Flow
1
UOC
UBS O'Connor
Illinois
-$575K
2
SM
Sabby Management
Florida
-$103K
3
TSS
Two Sigma Securities
New York
-$23K
4
UBS Group
UBS Group
Switzerland
-$22K
5
Bank of New York Mellon
Bank of New York Mellon
New York
-$8K
Name Holding Trade Value Shares
Change 		Change in
Stake
SMV
1
Sofinnova Management VIII
California
$6.41M – – –
BG
2
Bellevue Group
Switzerland
$1.78M – – –
TCM
3
Tekla Capital Management
Massachusetts
$635K – – –
Morgan Stanley
4
Morgan Stanley
New York
$447K +$122K +2 +40%
WA
5
Wasatch Advisors
Utah
$90K – – –
WS
6
Wedbush Securities
California
$36K – – –
SPC
7
Sigma Planning Corp
Michigan
$35K +$60.9K +1 New
ARTA
8
A.R.T. Advisors
New York
$16K – – –
Citadel Advisors
9
Citadel Advisors
Florida
$15K – – –
KeyBank National Association
10
KeyBank National Association
Ohio
$14K – – –
Geode Capital Management
11
Geode Capital Management
Massachusetts
$10K – – –
BTS
12
BB&T Securities
Virginia
$8K – – –
CG
13
Cutler Group
California
$3K – – –
UOC
14
UBS O'Connor
Illinois
– -$575K -10 Closed
SM
15
Sabby Management
Florida
– -$103K -2 Closed
Bank of New York Mellon
16
Bank of New York Mellon
New York
– -$8K – –
Creative Planning
17
Creative Planning
Kansas
– -$1K – –
TSS
18
Two Sigma Securities
New York
– -$23K – –
UBS Group
19
UBS Group
Switzerland
– -$22K – –

CYTO Hedge Fund Activity: Q3 2017 in Review

7 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q3 2017, worth a combined $9.5M — up 5.1% from $9.03M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of CYTO and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.

The largest buyer was Morgan Stanley, adding an estimated $122K. The largest seller was UBS O'Connor, exiting entirely with an estimated $575K sold.

  • 7 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q3 2017, down from 9 in Q2 2017.
  • Funds reported $9.5M of Altamira Therapeutics Ltd stock for Q3 2017, up 5.1% quarter-over-quarter.
  • 1 fund opened new Altamira Therapeutics Ltd positions in Q3 2017 and 2 closed out, a net change of -1 holder.
  • The largest Altamira Therapeutics Ltd buyer in Q3 2017 was Morgan Stanley, an estimated $122K added.
  • The largest Altamira Therapeutics Ltd seller in Q3 2017 was UBS O'Connor, an estimated $575K sold.

Based on aggregated 13F filings for Q3 2017.